Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong · Delayed Price · Currency is HKD 1.910
-0.085 (-4.26%)
Sep 11, 2026, 4:08 PM HKT
Clover Biopharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.43 | 3.51 | 38.42 | 39.26 | - | - | |
Revenue Growth | -99.17% | -90.88% | -2.13% | - | - | - |
Cost of Revenue | 5.96 | 0.2 | 711.36 | 1,712 | 475.64 | 66.27 |
Gross Profit | -5.53 | 3.31 | -672.94 | -1,673 | -475.64 | -66.27 |
Selling, General & Admin | 69.14 | 71.4 | 94.88 | 253.58 | 410.24 | 345.71 |
Research & Development | 203.93 | 182.34 | 183.39 | 649.89 | 1,465 | 1,826 |
Other Operating Expenses | 18.9 | 4.46 | 3.63 | 24.59 | 49.01 | 0.43 |
Operating Expenses | 291.97 | 258.2 | 281.9 | 928.05 | 1,925 | 2,172 |
Operating Income | -297.5 | -254.89 | -954.84 | -2,601 | -2,400 | -2,239 |
Interest Expense | -0.2 | -0.38 | -5.76 | -18.72 | -5.93 | -8.22 |
Interest & Investment Income | 2.7 | 6.33 | 23.69 | 16.12 | 8.51 | 10.89 |
Currency Exchange Gain (Loss) | 32.32 | 11.46 | -23.85 | -34.98 | -25.41 | 10.35 |
Other Non Operating Income (Expenses) | 27.25 | 36.13 | 16.58 | 12.43 | 14.51 | 16.11 |
EBT Excluding Unusual Items | -235.44 | -201.35 | -944.19 | -2,626 | -2,409 | -2,210 |
Merger & Restructuring Charges | - | - | - | - | -13.84 | - |
Gain (Loss) on Sale of Investments | 0.08 | 0.17 | 0.4 | - | 0.23 | 0.91 |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | 2 | -4.74 | -8.43 | - |
Asset Writedown | - | - | -14.01 | -10.31 | - | - |
Other Unusual Items | 1,087 | -3.9 | 52.37 | 2,503 | -21.32 | -3,808 |
Pretax Income | 851.15 | -205.09 | -903.43 | -138.54 | -2,452 | -6,016 |
Net Income | 851.15 | -205.09 | -903.43 | -138.54 | -2,452 | -6,016 |
Net Income to Common | 851.15 | -205.09 | -903.43 | -138.54 | -2,452 | -6,016 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,264 | 1,260 | 1,254 | 1,244 | 1,102 | 1,158 |
Shares Outstanding (Diluted) | 1,277 | 1,260 | 1,254 | 1,244 | 1,102 | 1,158 |
Shares Change | 1.58% | 0.53% | 0.82% | 12.83% | -4.84% | 52.85% |
EPS (Basic) | 0.67 | -0.16 | -0.72 | -0.11 | -2.22 | -5.19 |
EPS (Diluted) | 0.67 | -0.16 | -0.72 | -0.11 | -2.22 | -5.19 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -194.86 | -289.62 | -734.83 | -1,768 | -977 |
Free Cash Flow Per Share | - | -0.15 | -0.23 | -0.59 | -1.60 | -0.84 |
Gross Margin | - | 94.29% | - | - | - | - |
Operating Margin | -69186.51% | -7272.18% | -2485.33% | -6626.46% | - | - |
Profit Margin | 197942.79% | -5851.41% | -2351.51% | -352.92% | - | - |
Free Cash Flow Margin | - | -5559.46% | -753.84% | -1871.94% | - | - |
EBITDA | -281.66 | -237.82 | -926.43 | -2,563 | -2,371 | -2,226 |
D&A For EBITDA | 15.84 | 17.07 | 28.41 | 38.3 | 28.98 | 12.29 |
EBIT | -297.5 | -254.89 | -954.84 | -2,601 | -2,400 | -2,239 |